Prevenar 13®

Pneumococcal polysaccharide conjugate vaccine, 13-valent adsorbed

Providing New Zealand children with broader* protection against pneumococcal disease[1]

*Prevenar 13 protects against 13 serotypes vs. 10 serotypes with PCV10.[1]

Prevenar 13 dosing schedule in previously unvaccinated healthy children under 5 years[1†]

6 weeks of age → **5 months of age** → **12 months of age**

†An additional dose at 3 months should be administered ONLY to eligible high-risk children. Prevenar 13 is funded for extended pneumococcal immunisation to eligible high-risk individuals. Please refer to the New Zealand Immunisation Handbook for further information.[1]

Protection against the leading cause of invasive pneumococcal disease[2]

Prevenar 13 is a conjugate vaccine that helps protect against pneumococcal disease caused by 13 serotypes of *S. pneumoniae*, including **serotypes 3, 6A and 19A.**

Prevenar 13 provides protection against serotype 19A which has become a significant cause of pneumococcal disease amongst New Zealand children.[1-3]

Prevenar 13[1]

4	6B	9V	14	18C	19F	23F	1	5	7F	3	6A	19A

PCV10[1]

4	6B	9V	14	18C	19F	23F	1	5	7F

Ordering Prevenar 13

Refer to the ProPharma website for updates about ordering and logistics
www.propharma.co.nz

Prevenar 13 Pre-filled Syringe 0.5 mL x 1

ProPharma code: **1110738**

Prevenar 13 Pre-filled Syringe 0.5 mL x 10

ProPharma code: **1126196**

About Prevenar 13

Prevenar 13 is administered as a single 0.5 mL intramuscular injection.[3]

Prevenar 13 is generally well-tolerated and has a demonstrated safety profile.[3]

Prevenar 13 can be given at the same time as other routine childhood vaccinations except the quadrivalent meningococcal conjugate vaccine MenACWY-D, which should be given at least 4 weeks before or after PCV13.[1]

Prevenar - a brand trusted worldwide for over 20 years[4]

Prevenar 13 is included in 140 paediatric National Immunisation Programmes.[5‡]

Prevenar 13 has been helping to protect New Zealand children since 2010.[3]

‡As of September 2022.

Help protect New Zealand children from pneumococcal disease.

Before prescribing, review Data Sheet available from Medsafe (www.medsafe.govt.nz) or Pfizer New Zealand Limited (www.pfizer.co.nz) or call 0800 736 363.

Prevenar 13® (Pneumococcal polysaccharide conjugate vaccine, 13-valent adsorbed) suspension for I.M. injection. Contains 30.8 µg of pneumococcal purified capsular polysaccharides conjugated to non-toxic diphtheria CRM197 protein. Therapeutic Indications: Active immunisation for the prevention of disease caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in adults and children from 6 weeks of age. **Dose and Method of Administration:** 0.5 mL I.M. *Infants 6 weeks to 6 months of age:* 3 doses at least one month apart. A single booster should be given after 12 months of age, at least 2 months after the primary series. Alternative schedule when given as part of a routine immunisation program: 2 doses with the first dose given from the age of 2 months, a second dose 2 months later, and a booster dose between 11–15 months of age. *Previously unvaccinated children:* Varies with age at first dose, see full Data Sheet. *Children aged 12 months to 17 years* who have completed primary infant immunisation with 7vPCV and children 6 to 17 years who have received one or more doses of 7vPCV may receive 1 dose, at least 8 weeks after the final dose of 7vPCV. *Adults:* 1 dose. If sequential administration of Prevenar 13 and 23vPPV is considered, Prevenar 13 should be given first. *High Risk Individuals:* Up to 4 doses, depending on condition. The dosing schedule should be guided by official recommendations. **Contraindications:** Hypersensitivity to any component of the vaccine, or to diphtheria toxoid. Allergic or anaphylactic reaction following prior administration of 7vPCV. **Special Warnings and Precautions for Use:** Do not administer intravenously, intravascularly, intradermally or subcutaneously. Avoid injecting into, or near nerves or blood vessels. Do not inject into gluteal area. Postpone administration in acute, moderate or severe febrile illness. Only protects against *Streptococcus pneumoniae* serotypes included in the vaccine and may not protect all individuals from pneumococcal disease. Consider the risks of intramuscular (IM) injection in infants or children with thrombocytopenia or any coagulation disorder. Appropriate treatment and supervision must be readily available in case of a rare anaphylactic event. Prophylactic antipyretic medication is recommended for children receiving concomitant whole-cell pertussis vaccines and for children with seizure disorders or history of febrile seizures. Consider the potential risk of apnoea when administering to very premature infants. **Interactions with other Medicines:** Can be administered concomitantly, at different injection sites, with several other injectable vaccines. See DS for details. **Fertility, Pregnancy and Lactation:** Safety during pregnancy or lactation not established. Not recommended for use in pregnant women. See DS for details. **Undesirable Effects – *Very common/common:*** *Children 6 weeks to 5 years:* Injection site reactions (redness, pain, swelling), fever, diarrhoea, vomiting, decreased appetite, drowsiness/increased sleep; restless sleep/decreased sleep, rash, irritability. *Children and adolescents 5 to 17 years:* Irritability, injection site reactions (redness, pain, swelling), somnolence, poor quality sleep, injection site tenderness (including impaired movement), fever, decreased appetite, vomiting, diarrhoea, headaches, rash. *Adults:* Diarrhoea, vomiting, chills, fatigue, injection site reactions (redness, pain, swelling), limitation of arm movement, fever, new or aggravated joint or muscle pain, decreased appetite, headaches, rash. **Adverse Effects – *Serious:*** Hypersensitivity reaction; anaphylactic/anaphylactoid reaction including shock; angioedema; erythema multiforme. Seizures, hypotonic-hyporesponsive episode in children. Others, see full Data Sheet. **Medicines Classification:** Prescription Medicine. Prevenar 13 is a fully funded prescription medicine for healthy previously unvaccinated children <5 yrs (from 1 December 2022), and adults and children with certain risk conditions (see PHARMAC criteria - Online Pharmaceutical Schedule). For individuals not meeting these criteria, Prevenar 13 is an unfunded prescription medicine – a prescription charge may apply. ® Registered Trademark. V10321.

References: 1. Manatū Hauora Ministry of Health. Immunisation Handbook 2020. 16.Pneumococcal disease. Available from: https://www.health.govt.nz/system/files/documents/pages/immunisation-handbook-16-pneumococcal-disease-v11.pdf (Accessed January 2022). **2.** Invasive Pneumococcal Disease Quarterly Report July-September 2022. ESR Science for Communities. Available from: https://surv.esr.cri.nz/PDF_surveillance/IPD/2022/2022Q3_IPDReport.pdf (Accessed January 2022). **3.** PREVENAR 13 Approved Data Sheet. **4.** Wasserman M *et al. Expert Review of Vaccines.* 2018;17(1):71-78. **5.** Data on File. Prevenar 13 Childhood NIP tracker, September 2022.

Pfizer New Zealand Limited, Auckland New Zealand. PP-PRV-NZL-0009. February 2023.
TAPS NP18913. PF11409.

Prevenar 13® Pneumococcal polysaccharide conjugate vaccine, 13-valent adsorbed

Pfizer